Adaptive Biotechnologies Corporation provided revenue guidance for the first quarter ended March 31, 2024. For the period, total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.775 USD | +0.91% | +7.36% | -43.47% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-43.67% | 405M | |
-20.19% | 10.81B | |
+51.66% | 3.36B | |
-33.83% | 2.22B | |
-14.15% | 2.16B | |
-27.37% | 1.55B | |
+21.15% | 1.04B | |
-2.62% | 746M | |
-32.25% | 425M | |
+29.03% | 378M |
- Stock Market
- Equities
- ADPT Stock
- News Adaptive Biotechnologies Corporation
- Adaptive Biotechnologies Corporation Provides Revenue Guidance for the First Quarter Ended March 31, 2024